

## ORIGINAL RESEARCH

### **Comparison of Sequential Boost and Simultaneous Integrated Boost Volumetric Modulated Arc Therapy in Treatment of Head and Neck Carcinoma: A Prospective Interventional Study**

<sup>1</sup>Abhishek Arora, <sup>2</sup>Ramesh Purohit, <sup>3</sup>Kiran Chigurupalli, <sup>4</sup>Menal Bhandari, <sup>5</sup>Ar Gupta, <sup>6</sup>Shalu Peter

<sup>1</sup>Resident, <sup>2,3,4</sup>Assistant Professor, <sup>5</sup>Professor, <sup>6</sup>Medical Physicist, Department of Radiation Oncology, Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India

#### **Corresponding author**

Ramesh Purohit

Assistant Professor, Department of Radiation Oncology, Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India

Email: [dr.ramesh1010@gmail.com](mailto:dr.ramesh1010@gmail.com)

Received: 21 December, 2022

Accepted: 28 January, 2023

#### **ABSTRACT**

**Introduction:** Volumetric Modulated Arc Therapy (VMAT) is a radiotherapy in head and neck cancer can be delivered by two boost techniques: Sequential Boost (SEQ) and Simultaneous Integrated Boost (SIB). There is still limited data comparing these two techniques.

**Aim:** To compare SEQ and SIB planning techniques of VMAT in patients of Head And Neck Squamous Cell Carcinoma (HNSCC) in terms of disease response and acute toxicities.

**Materials and Methods:** A prospective interventional study was conducted at Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India from January 2019 to December 2020. Fifty two patients of HNSCC planned for radical chemoradiation were enrolled into two study arms SEQ-VMAT and SIB-VMAT. Chemotherapy given as weekly cisplatin 40 mg/m<sup>2</sup>. Dosimetric comparison was done using Dose Volume Histogram (DVH) analysis. Response evaluation was done as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at 8-10 weeks follow-up. Acute toxicity evaluation was done as per Radiation Therapy Oncology Group (RTOG) toxicity grading. Statistical analysis was done using Statistical Package for Social Sciences (SPSS) version 20.0 software.

**Results:** A total of 52 subjects were included in the study, out of which 26 subjects were included in SEB group while 26 subjects in SIB group. No significant difference was observed in demographic data in terms of age 56.2 vs 53.5 years, sex (24 males and 2 females in both the arms), disease site (oropharynx is the most common site 38.5% in both arms) and stage (IVA 69.2% in SEQ arm vs 46.2% in SIB arm and III 30.8% in SEQ arm vs 42.3% in SIB arm). Dosimetric data was comparable between the two arms. SIB-VMAT shows significantly higher incidence of acute dermatitis (grade 1 dermatitis at two weeks 69.2% vs 38.5%, p=0.0279 and grade 2 dermatitis at six weeks 84.6% vs 38.5%, p=0.0007) and acute mucositis (grade 1 mucositis at two weeks 84.6% vs 38.5%, p=0.0007) as compared to SEQ-VMAT. SEQ- VMAT shows significantly higher incidence of dysphagia (grade 1 at four weeks 84.5% vs 50%, p=0.0087). No

**significant differences were observed in terms of xerostomia and laryngeal toxicity. No significant difference in overall response was observed between SIB vs SEQ (complete response 65.4% vs 53.85% p=0.40).**

**Conclusion: SEQ appears better in terms of acute toxicities but SIB was more convenient as no re-planning was required. For head and neck radiotherapy SIB and Sequential VMAT are comparable in terms of overall response.**

**Keywords: Head and neck, Radiotherapy, Chemoradiation**

## **INTRODUCTION**

With over 2,00,000 cases diagnosed in 2018, HNSCC cancers are one of the most common cancers in the Indian population [1]. In India, these tumours often present at a locally advanced stage [2]. Radiotherapy plays an important role in the treatment of HNSCC cancers, usually as curative treatment in pharyngeal, laryngeal and advanced oral cancer [3]. Radiotherapy for head and neck cancers can be challenging due to the complex anatomy and these tumours often located within close proximity to critical structures which can limit radiation dose [4]. VMAT is an advanced technique of Intensity-modulated Radiation Therapy (IMRT) which can achieve high conformity of dosage to target volumes with better sparing of normal tissues [5]. VMAT also has the potential to offer additional advantages, such as reduced treatment delivery time compared with conventional static field Intensity Modulated Radiotherapy (IMRT) [6,7].

VMAT allows treatment delivery by two different approaches: SEQ and SIB [8]. In SEQ technique, radiation dose is delivered in different phases with same dose per fraction. The SIB-IMRT technique is of particular interest because it can be used to increase the fraction dose to the boost volume while, at the same time, keeping the dose to the elective volume at a lower level [9]. SIB technique can also lead to reduction in overall treatment time and increase in both prescribed dose and biological dose [10]. There is limited data for normal tissue response in head and neck cancers treated with SIB technique. There is a substantial difference between the radio-biological response of the small high dose areas treated with increased dose per fraction inside intermediate dose volumes. Hence, there is a need to redefine the dosimetric and volumetric relationship for SIB [11]. Farzin M et al., have compared SIB vs. SEQ at other sites of body like high grade glioma of brain [12]. Hence, present study aims to compare the SEQ and SIB techniques of VMAT in patients of head and neck carcinomas in terms of acute toxicity and treatment response.

## **MATERIALS AND METHODS**

This prospective interventional study was conducted in Department of Radiation Oncology, Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India. The study was done from January 2019 to December 2020 with a median follow-up of 12.5 months. Fifty-two patients of biopsy proven squamous cell carcinoma of head and neck region were recruited in the study after an approval from Institutional Ethics Committee. (IEC No. GU/HREC/EC/2019/1558) and written informed consent.

## **INCLUSION CRITERIA**

Histopathologically proven primary HNSCC of either sex, who had calorie intake >1500 cal/day were included in the study.

## **EXCLUSION CRITERIA**

Patients with severe uncontrolled comorbidities, pregnant and lactating women, those who had received neo-adjuvant chemotherapy or prior radiotherapy and postoperative patients were excluded from the study.

## **SAMPLE SIZE CALCULATION**

95% confidence level, 80% power of study, pooled prevalence=0.27 and difference in proportion=0.25. Therefore, sample size was 24 for each group. Considering a 10% dropout rate, the sample size came out to be 24+2 for each study group. Hence n=26 for each study group.

## **PROCEDURE**

Patients of either sex above the age of 18 years with Eastern Cooperative Oncology Group (ECOG) performance status [13] of less than or equal to two were randomised into two arms, and treated with either SEQ-VMAT or SIB-VMAT. Patients were randomised in two study groups using online randomising software available at [www.randomiser.org](http://www.randomiser.org)-

- SEQ-VMAT

-SIB-VMAT

Pre-treatment evaluation including nutritional evaluation was done prior to treatment as per National Comprehensive Cancer Network Guidelines (NCCN) [13]. Assessment of extension of disease and staging was done by American Joint Committee of Cancer (AJCC) criteria along with clinical examination along with laryngoscopy, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) scan as required [14].

## **TREATMENT PLANNING**

All patients were immobilised in the supine position with a tailored head-shoulder four clamp thermoplastic mask to undergo CT simulation with slice thickness of 2.5 mm on GE Optima CT520 simulator. Target volume delineation was performed according to the International Committee for Radiological Units (ICRU) 83 guidelines [15]. Gross Tumour Volume (GTV) was defined as the gross extent of tumour shown by CT, MRI and PET, including all involved (positive) lymph nodes. On the basis of the primary tumour size and involved node, Clinical Target Volume- High Risk (CTV-HR), CTV- Intermediate Risk (CTV-IR) and CTV- Low Risk (CTV-LR) were contoured. Treatment volume definitions and expansions were consistent between SIB and SEQ groups and were individualised as per institutional practice. Normal and avoidance structures were contoured based on their anatomic definitions. Organs at risk included: spinal cord, brain stem, left and right parotids; larynx, oesophagus, trachea, mandible, pharyngeal constrictors and uninvolved oral cavity. Whenever close to the Planning Target Volume (PTV), eyeballs, optic nerves, and optic chiasm were contoured. PTV margin of 3 mm was generated over CTV for all patients. The dose was prescribed to the PTV using 95% isodose line in both the arms. The dose constraints to Organ At Risk (OAR) were prescribed using Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) [16]. Treatment planning was then performed using Monte-Carlo Optimiser on MONACO v5.11. VMAT plans were generated in both the study groups and plans were evaluated using dose-volume histograms. Dosimetric assessment was done using DVH.

## **TREATMENT EXECUTION**

Treatment was executed on Elekta Versa HD Linear Accelerator. Online image guidance in form of X-ray Volumetric Imaging (XVI) version 5.0 was taken daily or alternate days as per institutional practice. In SEQ boost arm, a 2 gray (Gy) dose per fraction was delivered in different phases and for SIB arm, dose ranging from 1.6 Gy to 2.2 Gy per fraction was delivered in a single treatment plan. For SEQ arm, planning was done in a phased manner. Modifications to original plan were made first at the end of fifth week and then at end of sixth week. Dose prescription, specification and reporting were performed according to ICRU 50

and 62 recommendations. All the patients were treated with conventional dose fractionation using a five-days per week treatment schedule.

Chemotherapy as indicated in both the study groups, consisted of weekly cisplatin 40 mg/m<sup>2</sup> with a ceiling dose of 70 mg. All patients had consultation with dietician and whenever required nasogastric feeding tube was placed if patient was unable to maintain nutrition. The acute toxicities were documented as per the RTOG Toxicity Criteria included skin, mucosa, salivary glands, pharynx/oesophagus and larynx. Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 [17] was used for response evaluation at the end of 8-10 weeks after the completion of radiotherapy. Patients were assessed clinically, laryngoscopic examination and imaging with CT/MRI/PET CT scan as required.

### STATISTICAL ANALYSIS

Data was presented as mean, standard deviation, median (range), or percentage. Statistical Analysis was done using the Statistical Software for Social Sciences (SPSS) version 20.0 (Chicago, IL). Chi-square test and t-test were used for comparison of qualitative and quantitative variables respectively. The p-value less than 0.05 were considered significant.

### RESULTS

Total of 52 patients (26 patients in SEQ VMAT group and 26 patients in SIB VMAT group) were included and data was collected for analysis. Demographic data showed no significant difference in both treatment arms in terms of age (56.2 years in SEQ vs 53.5 years in SIB arm, p-value=0.41), sex (24 males and 2 females in both the arms), disease site {oropharynx is the most common site 38.5% (10/26) in both arms} and stage at presentation {stage IVA constitutes 18(69.2%) patients in SEQ arm vs 12(46.2%) patients in SIB arm and stage III constitutes 8(30.8%) patients in SEQ arm vs 11 (42.3%) in SIB arm} [Table/Fig-1]. Majority of the patients were males {24(92.3%) in both the arms}.

[Table/Fig-1]: Patient Demographic Data (N=52).

**AJCC: American joint committee of cancer; SEQ: Sequential VMAT arm; SIB: Simultaneous integrated boost VMAT arm; PNS paranasal sinus**

Characteristics	Total (N=52)	SEQ (N=26)	SIB (N=26)	p-value
Age (years) Mean±SD	54.85±11.7	56.2±12.6	53.5±10.8	0.4107
<b>Sex</b>				
Male	48 (92.3%)	24 (92.3%)	24 (92.3%)	0.99
Female	4 (7.7%)	2 (7.7%)	2 (7.7%)	
<b>Primary Site</b>				
Oral cavity	12 (23.0%)	8 (30.8%)	4 (15.4%)	0.32
PNS	01 (1.9%)	1 (0.38%)	0	0.99
Oropharynx	20 (38.5%)	10 (38.5%)	10 (38.5%)	0.99
Larynx & Hypopharynx	19 (36.5%)	7 (26.9%)	12 (46.2%)	0.25
<b>AJCC Stage grouping</b>				
II	3 (5.7%)	0	3 (11.5%)	0.097
III	19 (36.5%)	8 (30.8%)	11 (42.3%)	
IVA	30 (57.7%)	18 (69.2%)	12 (46.2%)	

Toxicity assessment showed that 10 (38.5%) patients in SEQ arm experienced grade 1 acute dermatitis as compared to 18 (69.2%) patients in SIB arm at the end of 2 weeks. Similarly, Grade 2 Dermatitis was observed in 10 (38.5%) patients in SEQ arm vs 22 (84.6%) patients in SIB arm at the end of six weeks [Table/Fig-2]. Patients experiencing grade 1 acute mucositis were 10 (38.5%) patients in SEQ arm vs 22 (84.6%) SIB arm at the end of week-2 [Table/Fig-3]. Most of the patients observed either grade 1 or grade 2 acute xerostomia. Grade 3 or 4 acute xerostomia was observed in none of the patients [Table/Fig-4]. No major

differences were observed in terms of dysphagia and acute laryngeal toxicity in both the study arms [Table/Fig-5,6]. Complete response was observed in 14 (53.8%) in SEQ arm vs 17 (65.4%) patients in SIB arm, p-value=0.40 while a partial response was observed in 12 (46.1%) patients in SEQ arm vs 9 (34.6%) patients in SIB arm, p-value=0.40 when assessed at 8-10 weeks post- treatment [Table/Fig-7].

**[Table/Fig-2]: Dermatitis (N=52)**

**Grade 1: Faint erythema or desquamation; Grade 2: Moderate to brisk erythema or patchy, moist desquamation confined to skin folds and creases; Moderate swelling; Grade 3: Confluent, moist desquamation greater than 1.5 cm diameter, which is not confined to the skin folds**

Acute dermatitis		Grade 0	Grade 1	Grade 2	Grade 3
At 2 weeks	SEQ	16(61.5%)	10(38.5%)	0	0
	SIB	8 (30.8%)	18 (69.2%)	0	0
	p-value	0.0279	0.0279	-	-
At 4 weeks	SEQ	2 (7.7%)	19(73.1%)	5 (19.2%)	0
	SIB	0	24 (92.3%)	2 (7.7%)	0
	p-value	-	0.0699	0.2288	-
At 6 weeks	SEQ	0	15(57.7%)	10(38.5%)	1 (3.8%)
	SIB	0	3 (11.5%)	22 (84.6%)	1 (3.8%)
	p-value	-	0.0005	0.0007	1.00

**[Table/Fig-3]: Mucosal reactions (N=52).**

**Grade 0: no signs and symptoms; Grade 1: painless ulcers, edema, or mild soreness; Grade 2: painful erythema, edema, or ulcers but able to eat; Grade 3: painful erythema, edema, or ulcers but unable to eat**

Acute Mucositis		Grade 0	Grade 1	Grade 2	Grade 3
At 2 weeks	SEQ	14 (53.8%)	10 (38.5%)	2 (7.7%)	0
	SIB	4 (15.4%)	22 (84.6%)	0 (0%)	0
	p-value	0.0039	0.0007	-	-
At 4 weeks	SEQ	2 (7.7%)	19 (73.1%)	5 (19.2%)	0
	SIB	2 (7.7%)	13 (50%)	11 (42.3%)	0
	p-value	1.0	0.0900	0.0739	-
At 6 weeks	SEQ	0	10 (38.5%)	12 (46.1%)	4 (15.4%)
	SIB	0	5 (19.2%)	16 (61.6%)	5 (19.2%)
	p-value	-	0.1282	0.2828	0.7198

**[Table/Fig-4]: Xerostomia (N=52).**

**Grade 0: no symptoms; Grade 1: Mild Symptomatic -dry or thick saliva without advise of sig- nificant dietary alteration; Grade-2: Moderate Symptomatic and significant oral intake alteration advised; Grade 3: Severe Symptoms leading to inability to adequately aliment orally or parenteral nutrition indicated**

Acute Xerostomia		Grade 0	Grade 1	Grade 2
At 2 weeks	SEQ	13 (50%)	13 (50%)	0
	SIB	13 (50%)	13 (50%)	0
	p-value	1.0	1.0	-
At 4 weeks	SEQ	3(11.5%)	18 (69.2%)	5 (19.2%)
	SIB	6(23.1%)	18 (69.2%)	2 (7.7%)
	p-value	0.2735	1.0	0.2288
At 6 weeks	SEQ	0	13 (50%)	13 (50%)

	SIB	1 (3.8%)	12 (46.2%)	13 (50%)
	p-value	-	0.7860	1.0

[Table/Fig-5]: Dysphagia (N=52).

**Grade 0:** normal; **Grade 1:** within functional limits- abnormal oral or pharyngeal stage but able to eat a regular diet without modifications or swallowing precautions; **Grade 2:** mild impairment- mild dysfunction in oral or pharyngeal stage, requires a modified diet without need for therapeutic swallowing precautions; **Grade 3:** mild-to-moderate impairment with need for therapeutic precautions-requires a modified diet and therapeutic precautions to minimize aspiration risk

Acute dysphagia		Grade 0	Grade 1	Grade 2	Grade 3
At 2 weeks	SEQ	19 (73.1%)	7 (26.9%)	0	0
	SIB	15 (57.7%)	11 (42.3%)	0	0
	p-value	0.2477	0.2477	-	-
At 4 weeks	SEQ	3 (11.5%)	20 (84.5%)	3 (11.5%)	0
	SIB	7 (26.9%)	13 (50%)	6 (23.1%)	0
	p-value	0.1627	0.0087	0.2735	-
At 6 weeks	SEQ	0	10 (38.5%)	13 (50%)	3 (11.5%)
	SIB	0	13 (50%)	8 (30.8%)	5 (19.2%)
	p-value	-	0.4084	0.1624	0.4456

[Table/Fig-6]: Laryngeal toxicity.

**Grade 0:** no symptoms; **Grade 1:** mild hoarseness and dryness; **Grade 2:** Moderate hoarseness and dryness; **Grade 3:** Severe hoarseness with dyspnoea, moderate odynophagia and dysphagia

Total is different in all toxicities as some patients did not have the toxicities. One patient who had grade 0 toxicity at 2 weeks was managed conservatively, did not report any toxicity on 4 and 6 weeks

Acute laryngitis		Grade 0	Grade 1	Grade 2	Grade 3
At 2 weeks	SEQ	13 (65%)	7 (35%)	0	0
	SIB	13 (68.4%)	6 (31.6%)	0	0
	p-value	0.7967	0.7967	-	-
At 4 weeks	SEQ	5 (25%)	12 (60%)	3 (15%)	0
	SIB	3 (16.7%)	14 (77.8%)	1 (5.6%)	0
	p-value	0.4657	0.1697	0.2695	-
At 6 weeks	SEQ	1 (5%)	10 (50%)	7 (35%)	2 (10%)
	SIB	0	9 (50%)	8 (44.4%)	1 (5.6%)
	p-value	-	1.0	0.4927	0.5580

[Table/Fig-7]: Response evaluation (N=52).

**CR:** Complete response; **PR:** Partial response

Response at 8-10 weeks	CR		PR	
	N	%	N	%
SEQ	14	53.85	12	46.15
SIB	17	65.4	9	34.6
p-value	0.4006			

**[Table/Fig-8]: Dosimetric comparison.****SC: Spinal cord; \*t-test**

D Mean	SEQ			SIB			p-value* of D mean
	Mean	SD	N	Mean	SD	N	
Dmean Larynx	44.31	8.72	20	43.57	8.16	18	0.7921
Dmean Trachea	33.23	7.25	26	32.59	6.87	26	0.9302
Dmean Oesophagus	28.84	6.03	26	29.5	4.35	26	0.8011
Dmean Parotid Left	24.4	1.94	26	24.71	3.23	26	0.7543
Dmean Parotid Right	24.81	2.54	26	27.75	7.93	26	0.0778
Dmean Mandible	50.38	4.79	26	47.86	5.74	26	0.0918
Dmax SC	34.17	3.26	26	34.69	4.25	26	0.944
Dmax Brain Stem	6.06	4.69	26	4.94	2.14	26	0.1815

Dosimetric analysis was done comparing the mean doses to organs at risk for both the study groups and Planning Target Volume (PTV) coverage. No difference was observed in terms of target coverage for both techniques. Mean dose to larynx was  $44.31 \pm 8.72$  Gy in SEQ arm and  $43.57 \pm 8.17$  Gy in SIB arm, p-value=0.79. Similarly, dose to left and right parotid gland were  $24.4 \pm 1.94$  Gy and  $24.81 \pm 2.54$  Gy in SEQ arm and  $24.71 \pm 3.23$  and  $27.75 \pm 7.93$  Gy in SIB arm respectively, p-values 0.75 and 0.07 [Table/Fig-8].

**DISCUSSION**

The present prospective study evaluated and compared the acute toxicities and disease response between SEQ-VMAT vs SIB-VMAT for HNSCC. To our best knowledge this is the first randomised trial comparing SIB and SEQ boost using VMAT in non nasopharyngeal head and neck carcinoma. SEQ-VMAT and SIB-VMAT treatment in head and neck cancer are comparable in terms of overall response. Higher incidence of grade 1-2 acute dermatitis, mucositis and dysphagia was observed in SIB arm. No patient had treatment interruption due to acute toxicities. Toxicities were managed conservatively with use of topical anaesthetics, analgesics and opioids. Nutrition and hydration were maintained using dietician advised diet and iv fluids. There was no difference in the incidence of xerostomia and laryngeal toxicity. There was a trend towards higher incidence of grade 3 dysphagia in SIB arm but this was not found to be statistically significant. In present study, SEQ and SIB had comparable target coverage and dose to organs at risk. This was similar to the dosimetric studies done by Chen SW et al., and Nesrin D et al., comparing the target volume coverage and normal tissue sparing of SIB-IMRT versus SEQ-IMRT for nasopharyngeal carcinoma [18,19].

In a single institutional retrospective study by Vlacich G et al., performed matched cohort analysis on patients of locally advanced head and neck carcinoma treated with chemoradiation to 69.3 Gy in 33 fractions [20]. Out of 209 patients evaluated for analysis, 68 patients were treated with SEQ and 141 were treated with SIB. No significant difference was observed between SEQ versus SIB in disease free survival (63% vs 69%; p=0.27) and overall survival (69.3% vs 76.8%; p=0.13). They observed a significantly higher incidence of grade 3 or 4 acute dysphagia (82% vs 55%) and arms have equivalent dose prescription to the target volumes in terms of biological effective dose. Disease progression was observed in two patients in SIB arm and four in SEQ arm. No distant failure was seen in this study.

**LIMITATION(S)**

Lack of assessment of late toxicities, disease free survival and overall survival analysis because of short follow up. Lack of blinding of the study participants and of the investigator was another limitation of this study.

**CONCLUSION(S)**

For head and neck cancers, radical radiotherapy by SIB- and Sequential-VMAT planning are comparable in terms of overall response. But SIB arm had higher rates of acute dermatitis and mucositis. Dosimetric data was comparable between the two arms but SIB-VMAT was more convenient as no re-planning was required as compared to SEQ-VMAT.

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2021. <https://doi.org/10.3322/caac.21609>
2. Tuljapurkar V, Dhar H, Mishra A, Chakraborti S, Chaturvedi P, Pai PS. The Indian scenario of head and neck oncology - Challenging the dogmas. *South Asian J Cancer*. 2016;5(3):105-10.
3. Sweeney PJ, Haraf DJ, Vokes EE, Dougherty M, Weichselbaum RR. Radiation therapy in head and neck cancer: indications and limitations. *Semin Oncol*. 1994;21(3):296-303. PMID: 8209262.
4. Yeh S. Radiotherapy for head and neck cancer. *Seminars in Plastic Surgery*. 2010;24(02):127-36.
5. Teoh M, Clark C, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. *The British Journal of Radiology*. 2011;84(1007):967-96.
6. Verbakel WF, Cuijpers JP, Hoffmans D, Bieker M, Slotman BJ, Senan S. Volumetric intensity modulated arc therapy vs. conventional IMRT in head and neck cancer: a comparative planning and dosimetric study. *Int J Radiat Oncol Biol Phys*. 2009;74(1):252-59.
7. Vanetti E, Clivio A, Nicolini G, Fogliata A, Ghosh-Laskar S, Agarwal J, et al. Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: A treatment planning comparison with fixed field IMRT. *Radiotherapy and Oncology*. 2009;92(1):111-17.
8. Johnston M, Clifford S, Bromley R, Back M, Oliver L, Eade T. Volumetric modulated arc therapy in head and neck radiotherapy: A planning comparison using simultaneous integrated boost for nasopharynx and oropharynx carcinoma. *Clin Oncol (R Coll Radiol)*. 2011;23:503-11. DOI: 10.1016/j.clon.2011.02.002
9. Studer G, Huguenin PU, Davis JB, Kunz G, Lütolf UM, Glanzmann C. IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients. *Radiat Oncol*. 2006;1:7. doi: 10.1186/1748-717X-1-7
10. Jang S, Pyakuryal A, Cahlon O, Greenberg A, Tsai H, Lee S, et al. SU-E-T-595: A study of sequential and simultaneously integrated boost IMRT methods in head and neck cancer. *Medical Physics*. 2013;40(6Part20):342-42.
11. Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P. Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: A review. *Critical Reviews in Oncology/Hematology*. 2010;73(2):111-25.
12. Farzin M, Molls M, Astner S, Rondak I, Oechsner M. Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas. *Strahlentherapie und Onkologie*. 2015;191(12):945-52.
13. Guidelines With Evidence Blocks [Internet]. NCCN. 2021 [cited 9 November 2021]. Available from: <https://www.nccn.org/guidelines/guidelines-with-evidence-blocks>
14. AJCC Cancer Staging Handbook: TNM Classification of Malignant Tumors; SpringerLink; <https://link.springer.com/book/9783319406176>
15. The International Commission on Radiation Units and Measurements. *Journal of the*



- ICRU. 2010;10(1):NP.2-NP.
16. Bentzen S, Constine L, Deasy J, Eisbruch A, Jackson A, Marks L, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An introduction to the scientific issues. *Int J Radiat Oncol Biol Phys*. 2010;76(3):S3-S9. doi: 10.1016/j.ijro.2008.10.026.
  17. Eisenhauer E, Verweij J. New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1. *European Journal of Cancer Supplements*. 2009;7(2):5.
  18. Chen SW, Yang SN, Liang JA, Shiau AC, Lin FJ. Comparative dosimetric study of two strategies of intensity-modulated radiotherapy in nasopharyngeal cancer. *Med Dosim*. 2005;30(4):219-27.
  19. Nesrin D, Stephen K, Bahman E, Najeeb M, Nena M, Leonid BL, et al. Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing. *Int J Radiat Oncol Biol Phys*. 2003;57(5):1480-91.
  20. Vlacich G, Stavas M, Pendyala P, Chen S, Shyr Y, Cmelak A. A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer. *Radiation Oncology*. 2017;12(1); 13: doi: 10.1186/s13014-016-0756-x
  21. Songthong A, Kannarunimit D, Chakkabat C, Lertbutsayanukul C. A randomised phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events. *Radiation Oncology*. 2015;10(1); 166: doi: 10.1186/s13014-015-0472-y
  22. Scorsetti M, Fogliata A, Castiglioni S, Bressi C, Bignardi M, Navarria P, et al. Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients. *Radiation Oncology*. 2010;5(1); 93: <https://doi.org/10.1186/1748-717X-5-93>
  23. Jiang L, Zhang Y, Yang Z, Liang F, Wu J, Wang R. A comparison of clinical outcomes between simultaneous integrated boost (SIB) versus sequential boost (SEQ) intensity modulated radiation therapy (IMRT) for head and neck cancer: A meta-analysis. *Medicine (Baltimore)*. 2019;98(34):e16942.